ارزيابي ميزان بيان has-miR-492 به عنوان يك ماركر مولكولي در بافت هاي پارافينه سرطان سينه و تخمدان و همراهي آن با فاكتورهاي باليني: يك مطالعه مورد- شاهدي

EVALUATION OF -MIR-492 EXPRESSION AS A BIOMARKER IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUES OF BREAST and OVARIAN CANCER and ITS ASSOCIATION WITH CLINICAL FACTORS: A CASE-CONTROL STUDY

پيش زمينه و هدف سرطان سينه و تخمدان شايع ترين بدخيمي و علت مرگ ومير در زنان در سراسر جهان هستند. بروز اين سرطان ها در سال هاي اخير به طور قابل توجهي در حال افزايش است. شواهد بسياري نشان داد كه بعضي از miRNA ها به عنوان مهاركننده تومور يا انكوژن در توسعه سرطان هاي مختلف عمل مي كنند. بااين حال، رابطه بين سرطان سينه و تخمدان و بيان miR-492 هنوز مشخص نشده است. در اين مطالعه، ما نقش miR-492 در سرطان سينه و تخمدان را بررسي كرديم. مواد و روش ها در مطالعه حاضر براي بررسي بيان ژن 40 بافت توموري و 40 بافت غيرتوموري پارافينه سرطان سينه و تخمدان انتخاب شدند. بعد از تكميل رضايت نامه، اطلاعات باليني مربوط به تمام نمونه ها گرفته شد. پس از استخراج RNA تام و سنتز DNA مكمل، بيان نسبي ژن با استفاده از روش كمي Real time PCR سنجيده و به وسيله روش 2-ΔΔct ارزيابي شد. نهايتا الگوي بياني توسط آناليزهاي آماري بررسي شد. يافته ها نتايج بررسي تغييرات بيان miR-492 نشان داد كه، در نمونه هاي توموري سينه/ تخمدان بيان اين miRNA به صورت معناداري افزايش يافت(P=0.0001) از طرفي، بين بيان ژن و درجه توموري ارتباط معناداري وجود نداشت (0.05

Background & Aims: Breast and ovarian cancer are the most common types of malignancy and the leading cause of death in females around the world. The incidence of these cancers has been experiencing a significant rise in recent years. Increasing evidence indicated that some miRNAs act as either tumor suppressors or promoters in the development of various cancers. However, the relationship between breast and ovarian cancer and the expression of miR-492 has not yet been elucidated. In this study, we explored the role of miR-492 in breast and ovarian cancer. Materials & Methods: In the present study, 40 formalin-fixed paraffin-embedded tumoral tissues and 40 non-tumoral tissues of breast and ovarian cancers were selected to evaluate gene expression. Then, the informed consent letters were collected and clinical information for all samples were completed. Total RNA was extracted and complementary DNA was synthesized, afterward, the relative gene expression was determined using a quantitative real-time RT PCR method and evaluated by the 2-ΔΔct method. Finally, the expression pattern was analyzed by statistical analysis. Results: The results of the changes in the expression of miR-492 showed that in tumoral samples, the expression of miR-492 increased significantly (P=0.0001). On the other hand, there was no significant relationship between gene expression and tumor grade (p>0.05). There was also a clear increase in the gene expression in the metastatic tumors. In breast cancer, unlike ovarian cancer, there was no statistically significant difference between the two age groups. In addition, a specific increase was observed in the gene expression in the metastatic state in ovarian tumors. The tumor position did not affect the level of miR-492 expression in ovarian cancer. Conclusion: Taken together, the data indicate that miR-492 is an important regulator in cancer cell biological processes. Furthermore, we showed that miR-492 with diagnostic and prognostic ability can be a promising novel therapeutic target and biomarker for breast and ovarian cancer. Keywords: miR-492, Brest Cancer, ovarian cancer, biomarker